公司资料
Atara Biotherapeutics, Inc. 股价、新闻与催化剂
- 股票代码:
- ATRA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
8.36 USD (+3.34%)
收盘价
最后更新: 2026年8月17日
89.2M USD
市值
股价为何变动
As of Aug 17, 2026, ATRA closed up 3.34% at $8.36. No new same-company headline was identified in the current news window.
公司概览
Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing.
Tabelecleucel
Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The U.S. application is supported by the pivotal single-arm ALLELE study.
Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program. Atara supports the BLA resubmission and retains eligibility for an approval milestone, commercial milestones, and tiered royalties.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。